Alkermes Plc

Alkermes Plc

Alkermes Plc

Overview
Date Founded

2011

Headquarters

1 Burlington Road, Connaught House, Dublin, D04 C5Y6, IRL

Type of Company

Public

Employees (Worldwide)

2,235

Industries

Pharmaceuticals
Biotechnology

Company Description

Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies, and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Contact Data
Trying to get in touch with decision makers at Alkermes Plc? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Senior Vice President, Chief Financial & Accounting Officer

Executive Vice President & Chief Operating Officer

Chief Commercial Officer & Senior Vice President

Senior Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary

Senior Vice President, IT & Chief Information Officer

Senior Vice President, Regulatory Affairs & Knowledge Management Services

Senior Vice President, Policy & Government Relations

Senior Vice President, Corporate Development

Senior Vice President-Operations, Quality & Safety

Board of Directors

Chief Executive Officer at Alkermes Plc

Executive Vice President, Chief Financial Officer & Treasurer at IDEXX Laboratories, Inc.

Director-Albright Institute at Wellesley College

Director at Alkermes, Inc.

Former Executive Vice President & Chief Commercial Officer at Vertex Pharmaceuticals, Inc.

Former Senior Vice President, Chief Financial Officer & Chief Accounting Officer at PerkinElmer, Inc.

Director at Us Foundation of The University of The Valley of Guatemala

President of Research & Development at BioNTech US, Inc.

Former Senior Managing Director at The Boston Company Asset Management LLC

Senior Advisor at The Monitor Group, Inc. - Georgia

Paths to Alkermes Plc
Potential Connections via
Relationship Science
You
Alkermes Plc
Owners & Shareholders
Details Hidden

Sarissa Capital Management seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. Sarissa Capital Management conducts rigorous, fundamentals-based research. The funds’ portfolios will consist largely of exchange-traded securities (mostly equities but including equity-linked derivatives such as total return swaps and options), but the funds may also invest in a broad range of other financial instruments including, but not limited to, over-the-counter (OTC) equity securities and equity linked derivatives such as total return swaps and options (including index funds), privately placed securities of public issuers, preferred stock, currencies and fixed income securities (including credit default swaps).

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, the firm may occasionally invest in other sectors if more attractive opportunities are identified. Camber Capital Management employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Recent Transactions
Details Hidden

Alkermes, Inc., Alkermes Plc purchase Rodin Therapeutics, Inc. from Johnson & Johnson Innovation JJDC, Inc., Atlas Venture, Inc., Hatteras Venture Partners, Third Point Ventures LLC, Google Ventures, Remeditex Ventures LLC

Details Hidden

Recro Pharma, Inc., Recro Pharma LLC purchase Alkermes Gainesville LLC from Alkermes Plc

Details Hidden

Alkermes Plc issued USD Ordinary Shares

Transaction Advisors
Legal Advisor

Advised onRecro Pharma, Inc., Recro Pharma LLC purchase Alkermes Gainesville LLC from Alkermes Plc

Underwriter

Advised onAlkermes Plc issued USD Ordinary Shares

Underwriter

Advised onAlkermes Plc issued USD Ordinary Shares

Legal Advisor

Advised onAlkermes Plc issued USD Ordinary Shares

Legal Advisor

Advised onAlkermes, Inc., Alkermes Plc purchase Rodin Therapeutics, Inc. from Johnson & Johnson Innovation JJDC, Inc., Atlas Venture, Inc., Hatteras Venture Partners, Third Point Ventures LLC, Google Ventures, Remeditex Ventures LLC

Associate

Advised onAlkermes, Inc., Alkermes Plc purchase Rodin Therapeutics, Inc. from Johnson & Johnson Innovation JJDC, Inc., Atlas Venture, Inc., Hatteras Venture Partners, Third Point Ventures LLC, Google Ventures, Remeditex Ventures LLC

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include AMPYRA (dalfampridine), INBRIJA (levodopa inhalation powder), BTT1023 (timolumab), SYN120, rHIgM22, and GGF2 (Cimaglermin alfa). The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Key Stats and Financials As of 2019
Market Capitalization
$3.55B
Total Enterprise Value
$2.96B
Earnings Per Share
$-1.25
Net Profit
$-197M
EBITDA
$4.94M
EBITDAMargin
0.42%
Total Debt
$291M
Total Equity
$1.09B
Enterprise Value / Sales
2.53x
Enterprise Value EBITDAOperating
596.96x
TEVNet Income
-15.05x
Debt TEV
0.1x
Revenue
$1.17B
Five Year Compounded Annual Growth Rate Of Revenue
13.61%
Three Year Compounded Annual Growth Rate Of Revenue
16.23%
Investments
Details Hidden

Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY.

Details Hidden

At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases and cancer. Since our founding in 2004, Acceleron has brought four distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.

Details Hidden

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

Suppliers
Veeva Systems, Inc. Other Business & Consulting Services | Pleasanton, CA

Veeva Systems, Inc. provides industry-specific, cloud-based software solutions for the life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage a regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. Veeva Systems was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Model N, Inc. IT Consulting & Services | Redwood City, CA

Model N, Inc. engages in the provision of revenue management cloud solutions for the life science and technology industries. Its solutions include two complementary suites of software applications: Revenue Management Enterprise and Revenue Management Intelligence. The Revenue Management Enterprise suite serves as the system of record for and automates the execution of revenue management processes such as pricing, contracting and incentive & rebate management. The Revenue Management Intelligence suite provides analytical insights to define and optimize revenue management strategies. The company was founded by Yarden Malka, Zack Rinat and Ali Tore on December 14, 1999 and is headquartered in San Mateo, CA.

Cambridge Cognition Holdings Plc Hospitals & Patient Services | Bottisham, United Kingdom

Cambridge Cognition Holdings Plc is a neuroscience digital health company, which engages in the development of digital health products to better understand, detect, and treat conditions affecting brain health. It operates through the following segments: Software, Services, and Hardware. The company's products include drug development, cognitive research, and healthcare technology. The company was founded on September 12, 2012 and is headquartered in Cambridge, the United Kingdom.

Competitors
H. Lundbeck A/S Pharmaceuticals - Valby, Denmark

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Biogen, Inc. Biotechnology - Canyon Country, CA

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alkermes Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alkermes Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Alkermes Plc.